The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Open accessAbstract
Key Points: This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348896 · Cited by 222
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.190 · Cited by 197
Research works printed but not linked: 28
- Dimopoulos, 2009, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma., Leukemia, 23, 2147, 10.1038/leu.2009.147 · DOI · Paper page
- Orlowski, 2007, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression., J Clin Oncol, 25, 3892, 10.1200/JCO.2006.10.5460 · DOI · Paper page
- Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma., N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
- Anderson, 2009, Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study., J Clin Oncol, 2009, 8536, 10.1200/jco.2009.27.15_suppl.8536 · DOI
- Jimenez-Zepeda, 2013, Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma., Leuk Lymphoma, 54, 555, 10.3109/10428194.2012.719614 · DOI
- Mikhael, 2012, Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis., Blood, 119, 4391, 10.1182/blood-2011-11-390930 · DOI · Paper page
- Reeder, 2009, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial., Leukemia, 23, 1337, 10.1038/leu.2009.26 · DOI · Paper page
- Reeder, 2010, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma., Blood, 115, 3416, 10.1182/blood-2010-02-271676 · DOI · Paper page
- Mai, 2015, Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma., Leukemia, 29, 1721, 10.1038/leu.2015.80 · DOI
- Richardson, 2009, Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma., J Clin Oncol, 27, 5713, 10.1200/JCO.2009.22.2679 · DOI · Paper page
- Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma., Blood, 116, 679, 10.1182/blood-2010-02-268862 · DOI · Paper page
- Richardson, 2014, A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma., Blood, 123, 1461, 10.1182/blood-2013-07-517276 · DOI · Paper page
- Herndon, 2013, U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma., Clin Cancer Res, 19, 4559, 10.1158/1078-0432.CCR-13-0755 · DOI · Paper page
- Siegel, 2012, A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma., Blood, 120, 2817, 10.1182/blood-2012-05-425934 · DOI · Paper page
- Vij, 2012, An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma., Blood, 119, 5661, 10.1182/blood-2012-03-414359 · DOI · Paper page
- Vij, 2012, An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib., Br J Haematol, 158, 739, 10.1111/j.1365-2141.2012.09232.x · DOI · Paper page
- Schey, 2004, Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma., J Clin Oncol, 22, 3269, 10.1200/JCO.2004.10.052 · DOI · Paper page
- Durie, 2006, International uniform response criteria for multiple myeloma., Leukemia, 20, 1467, 10.1038/sj.leu.2404284 · DOI · Paper page
- Bladé, 1998, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant., Br J Haematol, 102, 1115, 10.1046/j.1365-2141.1998.00930.x · DOI · Paper page
- Niesvizky, 2013, Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma., Clin Cancer Res, 19, 2248, 10.1158/1078-0432.CCR-12-3352 · DOI
- Mikhael, 2013, A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma: final results of MTD expansion cohort [abstract]., Blood, 122, 3179, 10.1182/blood.V122.21.3179.3179 · doi:10.1182/blood.v122.21.3179.3179
- Sonneveld, 2013, Dose escalation phase 2 trial of carfilzomib combined with thalidomide and low-dose dexamethasone in newly diagnosed, transplant eligible patients with multiple myeloma. A trial of the European Myeloma Network [abstract]., Blood, 122, 688, 10.1182/blood.V122.21.688.688 · doi:10.1182/blood.v122.21.688.688
- Bringhen, 2013, A phase II study with carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma [abstract]., Blood, 122, 685, 10.1182/blood.V122.21.685.685 · DOI
- Shah, 2012, Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma [abstract]., Blood, 120, 10.1182/blood.V122.21.1982.1982 · doi:10.1182/blood.v122.21.1982.1982
- Berdeja, 2012, Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase I safety analysis [abstract]., Blood, 120, 10.1182/blood.V120.21.4048.4048 · doi:10.1182/blood.v120.21.4048.4048
- Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]., Leukemia, 26, 149, 10.1038/leu.2011.196 · DOI · Paper page
- San Miguel, 2013, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial., Lancet Oncol, 14, 1055, 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
- Leleu, 2013, Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14) [abstract]., Blood, 122, 689, 10.1182/blood.V122.21.689.689 · DOI
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Self-citationSonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Metadata
- Authors
- Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W. I., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., Pascucci, N., Smith, D. D., Orlowski, R. Z., & Durie, B. G. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-11-12
- Volume
- 126
- Issue
- 20
- Pages
- 2284-2290
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2302708051
- Cited by
- 226
- References
- 7
- FWCI
- 23.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. https://app.cochat.ai/papers/10.1182/blood-2015-05-643320
- The paper
- Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W. I., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., Pascucci, N., Smith, D. D., Orlowski, R. Z., & Durie, B. G. M. (2015). Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. https://doi.org/10.1182/blood-2015-05-643320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.